This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). The word

January 2024 Ambition: Curing blood

cancers through cell and genome engineering Exhibit 99.1

This presentation (the

"Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). The words

"aim," "anticipate," "believe," "can," "could," "design," "enable" "estimate," "expect," "intend," "may,"

"ongoing," "plan," "potential," "project," "should," "target," "towards," "will," and similar expressions are intended to identify forward-looking

statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Presentation include those regarding the feasibility of a trem-cel (formerly VOR33) transplant to be successfully

manufactured, to engraft normally, to maintain blood counts following treatment with Mylotarg following allogeneic hematopoietic cell transplant and to be well tolerated, the potential of VCAR33ALLO in combination with trem-cel as a Treatment

System, the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts, the potential of Vor Bio's platform, Vor Bio's plans, strategies, expectations and anticipated

milestones for its preclinical and clinical programs, the availability and timing of results from preclinical studies and clinical trials, the timing of regulatory filings, the expected safety profile of Vor Bio's product candidates, cash

runway and expected capital requirements, and its plans and expectations related to the Company's manufacturing and facilities. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking

statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of

various factors, including: uncertainties inherent in the initiation, completion of, and availability and timing of results from, preclinical studies and clinical trials and clinical development of Vor Bio's product candidates; whether

preclinical data or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the uncertainty of regulatory approvals to conduct trials or to market products; the success of Vor

Bio's in-house manufacturing capabilities and efforts; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. The interim data for trem-cel presented in this

Presentation is based on five patients and future results for these patients or additional patients may not produce the same or consistent results. These and other risks are described in greater detail under the caption "Risk Factors"

included in Vor Bio's most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this Presentation speak only as of the date of

this Presentation, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law. Certain information contained in this

Presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and Vor Bio's own internal estimates and research. While we believe these third-party sources to be reliable as of the date

of this Presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third party sources. In addition, there can be no guarantee as to the

accuracy or reliability of any assumptions or limitations that may be included in such third-party information. While we believe our own internal research is reliable, such research has not been verified by any independent source. Disclaimer

Our Vision: Cure Blood Cancers Through

Cell and Genome Engineering Unique approach Positive clinical proof of concept VCAR33ALLO as of Sept. 30, 2023 Cash runway into 2H 2025 $160M In-house GMP manufacturing facility *tremtelectogene empogeditemcel, formerly VOR33 $160M in cash,

cash equivalents and marketable securities as of September 30, 2023. Fully owned CD33-directed transplant donor CAR-T Multiple sites activated Four modular clean rooms for clinical supply shielded stem cell transplants enabling targeted therapy

demonstrated in AML with CD33-deleted trem-cel* transplants

Current AML Disease State and Standard

of Care Conditioning Mobilize and collect stem cells from matched healthy donor Transplant Remission (MRD-) 2 0.8 Years Since HSCT Active disease Remission (MRD+) 0.0 0.2 0.4 0.6 0 Cumulative Incidence of Relapse 1 Status at Time of Transplant1

Despite transplantation, relapse is still common in AML patients 1 MRD: measurable residual disease; SOC: standard of care; HSCT: Hematopoietic Stem Cell Transplant 1 Araki et al, JCO 2016 4 Watchful Waiting 3 2 3 3 Standard of Care: Replace

Diseased Bone Marrow with Transplanted Healthy Donor Cells Toxic therapies to kill existing bone marrow Harvest Infuse stem cells into patient to restore the blood system Monitor for relapse; any follow-up treatment will damage the

Clear Unmet Need in AML ~200K

Post-transplant relapse, with <20% two-year survival3,4 50% Increase in # of AML transplants over the last 10 years2 ~20,000 People in the U.S. diagnosed with AML annually1 AML Transplants per year (U.S.)2 ~4,000 ~40% ~40% 1 American Cancer

Society 2023 2 Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides 2022 3 Araki et al, JCO 2016 4 Schmid et al, Blood 2012

Changing the Thinking on Tumor

Targeting Cancer antigens also expressed on healthy cells Biology: Overlapping Targets Limits treatment opportunities leading to poor outcomes Problem: On-target Toxicity Shielded transplants allowing therapies to be cancer-specific Solution:

Shielded Transplants

The Vision: eHSC + CAR-T Treatment

Systems CD33-directed antibody-drug conjugate CD33-directed transplant donor CAR-T therapy Clinical proof of concept Engraftment Heme protection VCAR33ALLO Healthy donor source, stemlike phenotype Tolerized to new marrow VCAR33AUTO Phase 1/2

NMDP-sponsored trial Addresses tumor heterogeneity and potential escape mechanisms Next-gen shielded HSC transplant Mylotarg Multi-targeted CAR-T therapy Trem-cel Trem-cel VCAR33 Multiplex-edited HSCs Multi-specific CAR-Ts Shielded CD33-deleted HSC

transplant Shielded CD33-deleted HSC transplant

Description Preclinical Clinical

Program / Trial Modality Indication Discovery/ Validation IND- Enabling Phase 1/2 Phase 2/3 Trem-cel + Mylotarg / VBP101 Shielded CD33-deleted transplant + CD33-directed ADC AML MDS, MPN MDS, MPN VCAR33ALLO (allogeneic) / VBP301 CD33-directed

transplant donor CAR-T AML Post-transplant VCAR33AUTO (autologous) CD33-directed autologous CAR-T AML Bridge-to-transplant Trem-cel + VCAR33 Treatment System Shielded CD33-deleted transplant + CD33-directed transplant donor CAR-T AML CD33-CLL1

Treatment System Multiplex-edited HSCs + Multi-specific CAR-T AML Expanding Pipeline Driven by Innovative Platform AML: acute myeloid leukemia; HSCs: hematopoietic stem cells; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm * The

VCAR33 construct is being studied in a Phase 1/2 clinical trial sponsored by the National Marrow Donor Program ("NMDP"), and the timing of data release is dependent on the investigators conducting the trial. NMDP-sponsored trial*

Discovery Platform Leveraging our proprietary Vor Bio platform, we are exploring additional surface targets such as CD123, EMR2, and CD5 including multiplex genome engineering approaches where multiple surface targets are removed. We are conducting

ongoing discovery efforts in commonly transplanted hematologic malignancies.

Proprietary Dual Cell Product

Potential Trem-cel Starting Material Apheresis Product from Healthy Matched Donor Trem-cel: CD33-deleted Shielded HSC Product VCAR33ALLO: CD33-targeted Transplant Donor CAR-T Therapy Cell selection Lentivirus transduction T cells CAR-T VCAR33ALLO

Material preparation Cell selection CRISPR/Cas9 engineering Engineered Hematopoietic Stem Cells (eHSCs) Treatment System uses non-stem cell fraction to make CAR-T from the same matched donor Unique In-house Manufacturing: Multi-product GMP facility

in Cambridge, MA Four independent clean rooms and on-site QA/QC Rapid manufacturing and release process fits into standard transplant procedure

Trem-cel + Mylotarg CD33-directed

antibody-drug conjugate CD33-directed Transplant Donor CAR-T therapy Clinical proof of concept Engraftment Heme protection VCAR33ALLO Healthy donor source, stemlike phenotype Tolerized to new marrow VCAR33AUTO Phase 1/2 NMDP-sponsored trial

Addresses tumor heterogeneity and potential escape mechanisms Next-gen shielded HSC transplant Mylotarg Multi-targeted CAR-T therapy Trem-cel Trem-cel VCAR33 Multiplex-edited HSCs Multi-specific CAR-Ts Shielded CD33-deleted HSC transplant Shielded

CD33-deleted HSC transplant

VBP101: Trem-cel + Mylotarg Phase

1/2a Clinical Trial Transplant Decision Infusion Donor Journey Related Unrelated Maintenance Mylotarg Manufacturing vein-to-vein 7-10 days Unedited back-up graft Transplant-eligible AML patients at high risk of relapse Trem-cel Manufacturing

~7-day process Engraftment No delay in typical patient transplant process If relapse occurs: Induction-course Mylotarg VCAR33ALLO (VBP301) Alternative treatments Starting ~day 60 up to 4 cycles dose escalation 0.5-2 mg/m2 Conditioning

Consolidation/Salvage Stem Cell Mobilization, Collection Screening Relapse-free survival Heme protection from Mylotarg Trem-cel engraftment Key Endpoints 01 02 03 Patient Journey

Patient Characteristics Pt Age/ Sex

Disease and Genetics Weight Donor, Dose, CD33 gene-editing efficiency 1 64/F AML-MRC Highly complex cytogenetics; CR2; TP53 mutation MRD: 1.8% 69.9 kg 10/10 HLA MUD 7.6 106 CD34 cells/kg, 88% CD33 gene editing 2 32/M AML after myeloid

sarcoma resected from abdomen Inv 16 and +22, t(3;3) 120.7 kg 10/10 HLA MUD 3.2 106 CD34 cells/kg, 87% CD33 gene editing 3 55/F AML-MRC DNMT3A, IDH2 and SMC1A mutations 114.1 kg 10/10 HLA MUD 2.6 106 CD34 cells/kg, 80% CD33

gene editing 4 68/M AML-MRC Complex cytogenetics; active disease; NRAS, ZRSR2, TET2 mutations MRD: 16% 72.4 kg 10/10 HLA MSD 5.8 106 CD34 cells/kg, 89% CD33 gene editing 5 66/M Secondary AML KIT D816V, CBL, SRSF2, RUNX1/2, BCORL1 mutations

102.1 kg 10/10 HLA MUD 4.6 106 CD34 cells/kg, 85% CD33 gene editing 6 63/F AML-MRC Highly complex cytogenetics; TP53, NRAS, WT1 mutations 66.2 kg 10/10 HLA MUD 5.7 106 CD34 cells/kg, 91% CD33 gene editing 7 67/M AML with recurrent

abnormalities CR2; NPM1, TET2, EZH2, SETBP1, PIGA mutations 72.8 kg 10/10 HLA MUD 9.4 106 CD34 cells/kg, 87% CD33 gene editing 8 57/M AML (myelomonocytic) with nml karyotype CR2 (CRi/CRp) 68.9kg 10/10 HLA MUD 9.5 106 CD34 cells/kg, 91%

CD33 gene editing MRC = myelodysplasia-related changes, MRD = Measurable Residual Disease, MUD = Matched Unrelated Donor, MSD = Matched Sibling Donor All patients received myeloablative conditioning with busulfan/melphalan/fludarabine/rabbit

anti-thymocyte globulin (ATG), with exception for patient #3, who received equine ATG. Data Cutoff: 4 Dec 2023. Presented data from EDC and site/PI communication; pending full source verification

Patient Clinical Timelines

(Patients 1-8) Patients Ineligible for Mylotarg: Patient 2 Secondary graft failure in context of prior sepsis, TMP-SMZ/possible DRESS and persistent hKU1 coronavirus infection. Graft failure resolved after back-up graft given. Patient 3 Immune

thrombocytopenia. Resolving after treatment with IVIg, steroids, rituximab, CD34 boost. Patient 4 CNS and systemic relapse prior to Mylotarg dosing. Days Post Transplant With Trem-cel Neutrophil engraftment Mylotarg infusion Discontinued Back-up

graft Relapse CD34 boost intended to overcome immune thrombocytopenia 0 30 60 90 120 180 210 240 150 270 300 (CD33+ relapse) Pt 3 Pt 5 Pt 2 Pt 4 Pt 1 Pt 6 Pt 7 Pt 8

Highly Efficient Removal of CD33

from Donor HSCs Proof of Concept: Successful Engraftment of CD33-Deleted HSCs CD33 editing efficiency (%) Arrows indicated day of individual patient neutrophil engraftment Neutrophil engraftment = 3 days 500 cells/L *Luznik L. et al. J Clin

Oncol 2022;40(4):356-368 Timely Post-transplant Neutrophil Engraftment Donor Chimerism (Day 28) 100% 100% 100% 100% 100% 100% 100% Median engraftment unmodified CD34+ graft* 100%

Mylotarg Causes Deep Cytopenias

Across Various Regimens Fostvedt et al. Clin Pharm Thera 2019;106(5):1006-1017 Platelet counts (cells/ L) 1000 10000 100000 10000 1000 100 10 Neutrophil counts (cells/ L)

Evidence of Protective Effect from

Mylotarg at 0.5 mg/m2 Mylotarg C1 Start: Pt 1 D+68; Pt 5 D+74; Pt 6 D+66 post-HCT Day from first Mylotarg dosing Mylotarg dose

Enrichment of CD33-negative Cells

following Mylotarg Myeloid Cells (Peripheral Blood) Days from first Mylotarg dosing Mylotarg dose

Patients 1, 5, 6: PK after 1st Dose

of Maintenance Mylotarg Pharmacokinetics VBP101 Relapsed/Refractory AML Population (Mylotarg Phase 1 Study 0903A1-101-US)1 Parameter Mean +/- SD 0.5 mg/m2 0.25 mg/m2 0.5 mg/m2 1 mg/m2 2 mg/m2 4 mg/m2 5 mg/m2 Cmax (ng/mL) 236 (+/- 151) 15 28 50

411 611 1,325 AUCinf (Hr*ng/mL) 10,890 (+/- 13958) 82 468 943 11,110 10,970 29,980 1Mylotarg ODAC 2017 Relationship Between Mylotarg Cmax and Veno-occlusive Disease in Prior Transplant1 Probability of Veno-occlusive Disease (%) Cmax after first dose

of Mylotarg (ng/mL) 2,000 4,000 6,000 8,000 10,000 0 95% CI Geometric mean (R/R AML) Mean VBP101 Cmax

VCAR33 CD33-directed antibody-drug

conjugate CD33-directed Transplant Donor CAR-T therapy Clinical proof of concept Engraftment Heme protection VCAR33ALLO Healthy donor source, stemlike phenotype Tolerized to new marrow VCAR33AUTO Phase 1/2 NMDP-sponsored trial Addresses tumor

heterogeneity and potential escape mechanisms Next-gen shielded HSC transplant Mylotarg Multi-targeted CAR-T therapy Trem-cel Trem-cel VCAR33 Multiplex-edited HSCs Multi-specific CAR-Ts Shielded CD33-deleted HSC transplant Shielded CD33-deleted HSC

A New Way of Generating CAR-T

Therapy T cells exactly matched to patient's new immune system, more likely to persist Stem-like, CAR-T cells more likely to expand and less prone to exhaustion Poor expansion and persistence Poorer clinical durability Exhausted, depleted T

cells High manufacturing failure Traditional Approaches Vor Bio Approach Autologous cells (derived from patient) Allogeneic cells (off-the-shelf) Transplant Donor Cells

VBP301: VCAR33ALLO Phase 1/2

Clinical Trial* Enroll VCAR33ALLO Infusion Prior Transplant Donor MRD+ or relapsed AML following SOC transplant or trem-cel transplant VCAR33ALLO Manufacturing ~7-day process Day 28 Follow-up Consent Collect 2nd transplant if required Arm B: MRD+

Arm A: Blasts 5% 3x3 dose escalation starting at 1 x 106 CAR+ cells/kg *Multiple active clinical sites that overlap with VBP101 trem-cel Phase 1/2a clinical study Lymphodepletion Disease control/response Expansion, persistence Safety Key

Endpoints 01 02 03 Patient Journey

VCAR33AUTO Shows Signs of Activity;

VCAR33ALLO Potentially More Active Autologous starting material 6-site IST Young adults and children (median 16 y, range 1-35) Academic manufacturing process Accepted for oral presentation at ASH N=24 enrolled, 19 infused Manageable tox (n=4 with

CRS Grade 3) Transplant donor starting material IND cleared in June, multiple sites opened Targeting ~12 sites Streamlined manufacturing process with objective of stem like cell phenotype Allows trem-cel patients to enroll Starting dose 1 x

106 CAR+ cells/kg VCAR33AUTO (NCI CD33CART) VCAR33ALLO Dose (CAR+ cells/kg) Total 3 x 105 1 x 106 3 x 106 1 x 107 # infused 19 3 3 7 6 (resp assess in 5) # with CR, (%) 2 (11%) 0 (0%) 0 (0%) 0 (0%) 2 (40%) Data from ASH 2023 Abstract:

Moving Beyond Proof of Concept to

Pivotal Targeting Short Registrational Pathway R/R AML Single Arm Pivotal Trials Fast Track granted on basis of trem-cel heme protection Exploring heme protection endpoints with agency Agent Indication # pts Endpoint Ivosidenib IDH1, Agios R/R AML